NSPR News and Press, InspireMD Inc. From 11/05/23

2023-11-05 11:08:50 ET Major earnings expected before the bell on Monday include: Axsome Therapeutics ( AXSM ) Brookfield Asset Management ( BAM ) BioNTech ( BNTX ) Ceragon Networks ( CRNT ) DISH Network ( DISH ) For further details see: N...

2023-11-03 12:13:27 ET More on InspireMD InspireMD Inc. (NSPR) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on InspireMD Historical earnings data for InspireMD Financial information for InspireMD For further details see: In...

TEL AVIV, Israel and MIAMI, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke, today announced that the Marvin Slosman, Chief Executive Offi...

TEL AVIV, Israel and MIAMI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today presented 30-day results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinica...

-Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Oct. 30, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke preve...

Provides additional treatment options for patients and treating physicians; likely expands CAS addressable market Potentially accelerates conversion of carotid interventions from surgery (carotid endarterectomy) to minimally invasive CAS and TCAR procedures InspireMD advancing b...

Announces hiring of Patrick Verta, MD, as Executive VP of Clinical and Medical Affairs Cheryl Tal joins as VP of Quality Assurance and Regulatory Affairs Shane Gleason, current General Manager of North America & VP of Global Marketing, promoted to Chief Commercial Officer ...

TEL AVIV, Israel, and MIAMI, Aug. 31, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract detailing upcoming 30-day results from its C-Guardians U.S. IDE clini...

2023-08-08 11:18:08 ET InspireMD Inc. (NSPR) Q2 2023 Results Conference Call August 08, 2023 8:30 AM ET Company Participants Glenn Garmont - IR Marvin Slosman - President, CEO and Director Amir Kohen - Interim CFO, Secretary and Treasurer Conference Call Pa...

2023-08-08 07:18:36 ET InspireMD press release ( NASDAQ: NSPR ): Q2 GAAP EPS of -$0.24 beats by $0.04 . Revenue of $1.65M (+7.8% Y/Y) beats by $0.08M . For further details see: InspireMD GAAP EPS of -$0.24 beats by $0.04, revenue of $1.65M beats by $0.08M